By Clinical Informatics News Staff
March 18, 2015 | Clinical Ink has merged with CentrosHealth,
joining Clinical Ink’s eSource solutions with CentrosHealth’s mobile apps for
clinical trial patient engagement and electronic patient reported outcomes
(ePRO). The merger brings MPM Capital and F2 Ventures to Clinical Ink’s list of
existing investors.
Clinical Ink also announced a strategic partnership with
Novartis Pharmaceuticals, as part of their Trials of the Future initiative, to
help drive industry-wide adoption of fully electronic clinical trials.
“The combination of Clinical Ink and CentrosHealth backed by
the deep expertise, relationships, and financial resources of MPM Capital creates
a powerful opportunity to transform the clinical development business model,”
said Ed Seguine, CEO of Clinical Ink, in a press release. “This multi-part transaction underscores the
tremendous progress we’ve made and the future potential for our combined
businesses to deliver innovative technology solutions that eliminate the root
causes of clinical trial inefficiency.
The involvement of Novartis is a significant validation of our
pioneering efforts to create a completely paperless clinical trial platform and
to reduce the cost, time and complexity of clinical research.”
By using CentrosHealth and SureSource, Clinical Ink’s award-winning
purpose-built eSource platform for research sites, research sponsors can
receive all of their data, both from the site and the patient, in real-time and
can dramatically reduce the cost, time, and complexity of the clinical trial
process.
“The CentrosHealth approach to patient engagement is based
on the simple premise that patients want to actively manage their participation
in clinical research,” said Jeremy Sohn, Founder/CEO of CentrosHealth. “Our platform seamlessly integrates clinical
trial activities such as medication reminders, visit scheduling, activity
measurements and ePRO into patients’ every-day life through personalized notifications,
text messages, calendar integration, and a highly functional mobile application
on their personal cellphone.”
As a result of this transaction representatives from MPM
Capital and F2 Ventures will join the existing board of directors of Clinical
Ink.